Journal
CLINICAL IMMUNOLOGY
Volume 137, Issue 1, Pages 41-50Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2010.06.002
Keywords
Multiple sclerosis; Natural killer receptors; LILRB1; CD56; Interferon-beta
Categories
Funding
- Spanish Ministry of Science an Innovation, MICINN [SAF2007-61814]
- Red HERACLES [RD06/0009]
- Ayudas Merck-Serono a la Investigacion
Ask authors/readers for more resources
NK cell receptors (NKR) are expressed in subsets of NK and CD8+ T cells, lymphocytes involved in multiple sclerosis (MS) pathogenesis. Clinical implications of NKR expression in MS are unknown. Here, we show that the proportions of CD8+ T cells displaying LILRB1, an inhibitory NKR expressed at late stages of T cell differentiation, were directly related with age and MS duration, and inversely with the immunomodulatory therapy-dependent increase of CD56(bright) NK cells. Similar associations were found for KIR+ and CD56+ CD8+ T cells, whereas no age-related NKR distribution was perceived in controls. Moreover, active MS had lower LILRB1+ NK cells, and IFN-beta-treated patients exhibited a phenotypic profile related to shorter disease evolution. Progressive accumulation of terminally differentiated T lymphocytes and experienced NK cells in MS, presumably stimulated in response to a persistent challenge and modulated by IFN-beta therapy, may support the analysis of NKR distribution as new biomarkers. (C) 2010 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available